Health Care & Life Sciences » Biotechnology | Elanix Biotechnologies AG

Elanix Biotechnologies AG | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
13.20
33.70
72.80
73.60
212.20
Total Accounts Receivable
-
-
86.10
70.50
914.00
Inventories
-
-
-
33.50
138.70
Other Current Assets
0.40
0.10
-
-
-
Total Current Assets
13.60
33.70
158.90
177.60
1,264.90
Net Property, Plant & Equipment
-
-
0.50
15.20
39.70
Total Investments and Advances
275.00
280.00
-
-
-
Intangible Assets
-
-
22,455.90
21,341.80
20,093.90
Total Assets
288.60
313.70
22,749.60
21,806.10
22,420.90
Accounts Payable
0.80
-
76.50
250.30
576.50
Other Current Liabilities
-
35.80
634.20
758.30
1,080.30
Total Current Liabilities
0.80
35.80
710.70
1,008.60
1,656.70
Provision for Risks & Charges
5.50
15.00
-
-
-
Deferred Taxes
-
-
5,030.60
4,576.80
3,538.90
Other Liabilities
-
-
797.20
515.10
168.40
Total Liabilities
6.30
50.80
6,672.70
6,372.00
6,386.50
Common Equity (Total)
282.30
262.90
16,076.90
15,434.00
16,034.50
Total Shareholders' Equity
282.30
262.90
16,076.90
15,434.00
16,034.50
Total Equity
282.30
262.90
16,076.90
15,434.00
16,034.50
Liabilities & Shareholders' Equity
288.60
313.70
22,749.60
21,806.10
22,420.90

About Elanix Biotechnologies

View Profile
Address
Hohenstaufenstrasse 1
Wiesbaden Hessen 65189
Germany
Employees -
Website http://www.elanix-biotechnologies.de
Updated 07/08/2019
Elanix Biotechnologies AG operates as a holding company, which engages in the development and marketing of progenitor cell-based products for acute wound care, as well as dermatological and gynecological applications. It operates through the Regenerative Medicine and Cosmetic Ointments business segments. The Regenerative Medicine segment offers skin dressings made from progenitor skin fibroblasts to provide protection and accelerated healing for burns and reconstructive surgery.